Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 312

1.

Update on immunopathogenesis and immunotherapy in multiple sclerosis.

Selter RC, Hemmer B.

Immunotargets Ther. 2013 Apr 25;2:21-30. doi: 10.2147/ITT.S31813. eCollection 2013. Review.

2.

B Lymphocytes in Multiple Sclerosis: Bregs and BTLA/CD272 Expressing-CD19+ Lymphocytes Modulate Disease Severity.

Piancone F, Saresella M, Marventano I, La Rosa F, Zoppis M, Agostini S, Longhi R, Caputo D, Mendozzi L, Rovaris M, Clerici M.

Sci Rep. 2016 Jul 14;6:29699. doi: 10.1038/srep29699.

3.

Diagnosis and Management of Multiple Sclerosis in Children.

Najafi MR, Najafi MA, Nasr Z.

Iran J Child Neurol. 2016 Summer;10(3):13-23. Review.

PMID:
27375751
4.

Identification of the Single Immunodominant Region of the Native Human CC Chemokine Receptor 6 Recognized by Mouse Monoclonal Antibodies.

Dorgham K, Dejou C, Piesse C, Gorochov G, Pène J, Yssel H.

PLoS One. 2016 Jun 23;11(6):e0157740. doi: 10.1371/journal.pone.0157740. eCollection 2016.

5.

T Lymphocyte Activation Markers as Predictors of Responsiveness to Rituximab among Patients with FSGS.

Chan CY, Liu ID, Resontoc LP, Ng KH, Chan YH, Lau PY, Than M, Jordan SC, Lam KP, Yeo WS, Yap HK.

Clin J Am Soc Nephrol. 2016 Aug 8;11(8):1360-8. doi: 10.2215/CJN.11941115. Epub 2016 Jun 7.

PMID:
27269610
6.

Pancreas-protective effect of rituximab for acute-onset type 1 diabetes in the honeymoon period: a case report.

Kurozumi A, Okada Y, Arao T, Miyazaki Y, Yoshikawa M, Torimoto K, Kubo S, Nakayamada S, Tanaka Y.

Endocrinol Diabetes Metab Case Rep. 2016;2016:160020. doi: 10.1530/EDM-16-0020. Epub 2016 May 1.

7.

Regulatory T Cell Dysfunction Acquiesces to BTLA+ Regulatory B Cells Subsequent to Oral Intervention in Experimental Autoimmune Encephalomyelitis.

Huarte E, Jun S, Rynda-Apple A, Golden S, Jackiw L, Hoffman C, Maddaloni M, Pascual DW.

J Immunol. 2016 Jun 15;196(12):5036-46. doi: 10.4049/jimmunol.1501973. Epub 2016 May 18.

PMID:
27194787
8.

Recent advances in the treatment of multiple sclerosis.

Bennett JL, Miravalle AA.

J Exp Pharmacol. 2010 Nov 2;2:155-61. doi: 10.2147/JEP.S7822. eCollection 2010. Review.

9.

Continuous inhibitory signaling by both SHP-1 and SHIP-1 pathways is required to maintain unresponsiveness of anergic B cells.

Getahun A, Beavers NA, Larson SR, Shlomchik MJ, Cambier JC.

J Exp Med. 2016 May 2;213(5):751-69. doi: 10.1084/jem.20150537. Epub 2016 Apr 25.

PMID:
27114609
10.

Rituximab efficiently depletes B cells in lung tumors and normal lung tissue.

Joly-Battaglini A, Hammarström C, Stankovic B, Aamodt H, Stjärne J, Brustugun OT, Helland Å, Øynebråten I, Corthay A.

F1000Res. 2016 Jan 8;5:38. doi: 10.12688/f1000research.7599.1. eCollection 2016.

11.

Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2.

Schulze-Topphoff U, Varrin-Doyer M, Pekarek K, Spencer CM, Shetty A, Sagan SA, Cree BA, Sobel RA, Wipke BT, Steinman L, Scannevin RH, Zamvil SS.

Proc Natl Acad Sci U S A. 2016 Apr 26;113(17):4777-82. doi: 10.1073/pnas.1603907113. Epub 2016 Apr 13.

12.

Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis.

Komori M, Lin YC, Cortese I, Blake A, Ohayon J, Cherup J, Maric D, Kosa P, Wu T, Bielekova B.

Ann Clin Transl Neurol. 2016 Feb 1;3(3):166-79. doi: 10.1002/acn3.293. eCollection 2016 Mar.

13.

CNS accumulation of regulatory B cells is VLA-4-dependent.

Lehmann-Horn K, Sagan SA, Winger RC, Spencer CM, Bernard CC, Sobel RA, Zamvil SS.

Neurol Neuroimmunol Neuroinflamm. 2016 Mar 9;3(2):e212. doi: 10.1212/NXI.0000000000000212. eCollection 2016 Apr.

14.

Myelin-reactive antibodies initiate T cell-mediated CNS autoimmune disease by opsonization of endogenous antigen.

Kinzel S, Lehmann-Horn K, Torke S, Häusler D, Winkler A, Stadelmann C, Payne N, Feldmann L, Saiz A, Reindl M, Lalive PH, Bernard CC, Brück W, Weber MS.

Acta Neuropathol. 2016 Jul;132(1):43-58. doi: 10.1007/s00401-016-1559-8. Epub 2016 Mar 29.

15.

TGF-β-Induced Regulatory T Cells Directly Suppress B Cell Responses through a Noncytotoxic Mechanism.

Xu A, Liu Y, Chen W, Wang J, Xue Y, Huang F, Rong L, Lin J, Liu D, Yan M, Li QZ, Li B, Song J, Olsen N, Zheng SG.

J Immunol. 2016 May 1;196(9):3631-41. doi: 10.4049/jimmunol.1501740. Epub 2016 Mar 21.

PMID:
27001954
16.

Autoantibody-boosted T-cell reactivation in the target organ triggers manifestation of autoimmune CNS disease.

Flach AC, Litke T, Strauss J, Haberl M, Gómez CC, Reindl M, Saiz A, Fehling HJ, Wienands J, Odoardi F, Lühder F, Flügel A.

Proc Natl Acad Sci U S A. 2016 Mar 22;113(12):3323-8. doi: 10.1073/pnas.1519608113. Epub 2016 Mar 8.

PMID:
26957602
17.

Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis.

Wootla B, Watzlawik JO, Stavropoulos N, Wittenberg NJ, Dasari H, Abdelrahim MA, Henley JR, Oh SH, Warrington AE, Rodriguez M.

Expert Opin Biol Ther. 2016 Jun;16(6):827-39. doi: 10.1517/14712598.2016.1158809. Epub 2016 Mar 10.

PMID:
26914737
18.

Immunopathology of Japanese macaque encephalomyelitis is similar to multiple sclerosis.

Blair TC, Manoharan M, Rawlings-Rhea SD, Tagge I, Kohama SG, Hollister-Smith J, Ferguson B, Woltjer RL, Frederick MC, Pollaro J, Rooney WD, Sherman LS, Bourdette DN, Wong SW.

J Neuroimmunol. 2016 Feb 15;291:1-10. doi: 10.1016/j.jneuroim.2015.11.026. Epub 2015 Dec 2.

PMID:
26857488
19.

The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects.

Sorensen PS, Blinkenberg M.

Ther Adv Neurol Disord. 2016 Jan;9(1):44-52. doi: 10.1177/1756285615601933. Review.

20.

Cytokine-Defined B Cell Responses as Therapeutic Targets in Multiple Sclerosis.

Li R, Rezk A, Healy LM, Muirhead G, Prat A, Gommerman JL, Bar-Or A; MSSRF Canadian B cells in MS Team.

Front Immunol. 2016 Jan 8;6:626. doi: 10.3389/fimmu.2015.00626. eCollection 2015. Review.

Items per page

Supplemental Content

Write to the Help Desk